Showing results (171-180 of 229) with videos related to
Sort By:
Pageof 23
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 3, 2019
ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease†N Colombo, C Sessa, A du Bois, et al.Ultrasound in Obstetrics & Gynecology : the Official Journal of the International Society of Ultrasound in Obstetrics and Gynecology|May 11, 2010
Ovarian cancer prediction in adnexal masses using ultrasound-based logistic regression models: a temporal and external validation study by the IOTA groupD Timmerman, B Van Calster, A C Testa, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 21, 2010
Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer: outcomes in the partially platinum-sensitive (platinum-free interval 6-12 months) subpopulation of OVA-301 phase III randomized trialA Poveda, I Vergote, S Tjulandin, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 21, 2010
Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer delays third-line chemotherapy and prolongs the platinum-free intervalS B Kaye, N Colombo, B J Monk, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 12, 2012
Applying the 2011 St Gallen panel of prognostic markers on a large single hospital cohort of consecutively treated primary operable breast cancersO Brouckaert, A Laenen, J Vanderhaegen, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 15, 2000
Oxaliplatin or paclitaxel in patients with platinum-pretreated advanced ovarian cancer: A randomized phase II study of the European Organization for Research and Treatment of Cancer Gynecology GroupM J Piccart, J A Green, A J Lacave, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 1, 2016
Health-related quality of life in women with recurrent ovarian cancer receiving paclitaxel plus trebananib or placebo (TRINOVA-1)K Fujiwara, B J Monk, C Lhommé, et al.European Journal of Cancer (Oxford, England : 1990)|June 4, 2014
BRCA1 gene promoter methylation status in high-grade serous ovarian cancer patients--a study of the tumour Bank ovarian cancer (TOC) and ovarian cancer diagnosis consortium (OVCAD)I Ruscito, D Dimitrova, I Vasconcelos, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 9, 2017
Bevacizumab with or after chemotherapy for platinum-resistant recurrent ovarian cancer: exploratory analyses of the AURELIA trialA Bamias, E Gibbs, C Khoon Lee, et al.European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|November 8, 2017
Rare ovarian tumours: Epidemiology, treatment challenges in and outside a network settingI Ray-Coquard, AnnaLisa Trama, M J Seckl, et al.Pageof 23